Logo for Guard Therapeutics Intl.

Guard Therapeutics Intl. Investor Relations Material

Latest events

Logo for Guard Therapeutics Intl.

R&D Update

Guard Therapeutics Intl.
Logo for Guard Therapeutics Intl.

Q3 2024

13 Nov, 2024
Logo for Guard Therapeutics Intl.

Q2 2024

22 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Guard Therapeutics Intl.

Access all reports
Guard Therapeutics International AB is a Swedish biopharmaceutical company focused on the development of therapies for the diagnosis and treatment of acute kidney injuries. The company is most known for its investigational drug, ROSGard, a biological candidate designed to prevent kidney damage by mimicking the body's defense system against oxidative stress, thereby protecting, cleaning, and repairing exposed cells and tissues. Guard Therapeutics is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq First North.